Skip to content

Effect of prophylactic use of esketamine on postpartum depression after spontaneous delivery: a randomized, double-blind, multicenter, prospective study

Effect of prophylactic use of esketamine on postpartum depression after spontaneous delivery: a randomized, double-blind, multicenter, prospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064467
Enrollment
Unknown
Registered
2022-10-09
Start date
2022-10-10
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum depressive state

Interventions

Group A:Esketamine 0.25mg/kg
Group B:Esketamine 0.125mg/kg
Group C:0.9% normal saline

Sponsors

Jiangsu Province Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. ASA I or II; 2. Aged range from 20 to 45 years; 3. BMI 18.5~30 kg/m^2; 4. Full-term, singleton, cephalic parturient; 5. Ask for pain relief during labor.

Exclusion criteria

Exclusion criteria: 1. Contraindications of esketamine use (such as hypertension patients); 2. Use sedative hypnosis, analgesia and antidepressants within a week; 3. Patients with a history of drug abuse; 4. History of other mental illnesses; 5. Severe heart, lung, liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Montgomery Depression Rating Scale (MADRS) Score;

Secondary

MeasureTime frame
Visual Analogue Scale Score for Pain;Maternal satisfaction;

Countries

China

Contacts

Public ContactHan Chuanbao

Jiangsu Province Hospital

mzhcb@126.com+86 13913026699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026